The management of Sopharma (

) has adopted a decision to list an emission of shares on Warsaw Stock Exchange (WSE), BSE reported.

The Board of Directors has authorized the company's executive director Ognyan Donev to take all necessary steps for the issuance of the stock.

In case of a successful listing, Sopharma will be the first Bulgarian company with stock traded both on BSE and on another regulated market.

Besides its strategic objectives in Poland, another reason for the company's listing on WSE is that it operates on the local market, Viktor Sobolevski, CEO of WSE said last week.

At the end of last week Sopharma signed a contract with Polish Natur Product Zdrovit for the establishment of a joint company.

Sopharma will control 50.01% of the new enterprise. The Polish company operates on the field of production and marketing of medical products. Its 2006 sales amounted to 101.8 mln Polish zloty, or 38.18 mln dollars.

Sopharma is present on the markets of Europe, Asia, Africa and North America. The company exports mainly to Russia, Ukraine, and Poland.

The pharmaceutical manufacturer has a 16.7% market share on the Polish market of prescription anti-smoking medicines, according to an IMS study.

Sopharma's stock added 2.27% today to an average of 8.11 leva. 51,866 shares changed hands on BSE today. Highest bids were at 9.327 leva and asks at 8.300.